Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Gilead Sciences, Inc.
< Previous
1
2
3
4
5
6
7
8
9
Next >
Gilead Sciences Announces Third Quarter 2021 Financial Results
October 28, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead and Merck Initiate Phase 2 Study Evaluating an Oral Weekly Combination Regimen of Investigational Lenacapavir and Investigational Islatravir for HIV-1 Treatment in Virologically Suppressed Adults
October 26, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
MRK
Gilead Presents Long-Term Switch Data Reinforcing Biktarvy® as a Treatment Option for a Broad Range of People Living With HIV
October 21, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead Sciences Announces Veklury® Donations to Help Address the Ongoing COVID-19 Crisis in Indonesia and Armenia
October 19, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
U.S. Food and Drug Administration Approves Expanded Indication of Gilead’s Biktarvy® for Treatment of HIV-1 in Pediatric Populations
October 18, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Sacituzumab Govitecan Receives Positive CHMP Opinion as 2L Treatment for Adult Patients With Metastatic Triple-Negative Breast Cancer
October 15, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead Sciences to Release Third Quarter 2021 Financial Results on Thursday, October 28, 2021
October 14, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
U.S. FDA Approves Kite’s Tecartus® as the First and Only Car T for Adults With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
October 01, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead Marks Fifth Approval for Trodelvy® in Metastatic Triple-Negative Breast Cancer Under Project Orbis Initiative with Health Canada Authorization
September 27, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Veklury® (Remdesivir) Significantly Reduced Risk of Hospitalization in High-Risk Patients with COVID-19
September 22, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead to Present Latest Antiviral Research Data Addressing Urgent Global Needs in Infectious Disease at IDWeek 2021
September 20, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
New Data Demonstrate Trodelvy® Survival Benefit in Metastatic Triple-Negative Breast Cancer Patients Regardless of Initial HR/HER2 Status
September 16, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Trodelvy® Significantly Improved Quality of Life Over Standard of Care in 2L+ Metastatic Triple-Negative Breast Cancer in Phase 3 ASCENT Study
September 16, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead to Present New Data at ESMO Congress 2021 Reinforcing the Practice-changing Potential of Trodelvy
September 13, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead Sciences to Present at Upcoming Investor Conference
September 01, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
European Medicines Agency Validates Gilead’s Marketing Authorization Application for Lenacapavir, an Investigational, Long-Acting Capsid Inhibitor for the Treatment of HIV-1 in People With Limited Therapy Options
August 19, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead Sciences Endows Its Foundation With More Than $200 Million to Support Health Justice, Community Giving and Employee Match Program
August 03, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead Sciences Announces Second Quarter 2021 Financial Results
July 29, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
BioNTech to Acquire Kite’s Neoantigen TCR Cell Therapy R&D Platform and Manufacturing Facility in Gaithersburg, MD
July 19, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
BNTX
GILD
New Phase 3 Data Support the Sustained, Long-Acting Efficacy of Lenacapavir, Gilead's Investigational HIV-1 Capsid Inhibitor
July 17, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Four-Year Biktarvy® Data Presented at IAS 2021 Demonstrate High Efficacy and Durable Viral Suppression in Treatment-Naïve Adults
July 17, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead Sciences to Release Second Quarter 2021 Financial Results on Thursday, July 29, 2021
July 15, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead to Present New Data at IAS 2021 Demonstrating the Company’s Commitment to Advancing Innovation in HIV Research
July 12, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead Submits New Drug Application to U.S. Food and Drug Administration for Lenacapavir, an Investigational, Long-Acting Capsid Inhibitor for the Treatment of HIV-1 in People With Limited Therapy Options
June 28, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Kite Announces Yescarta® CAR T-cell Therapy Improved Event-Free Survival by 60% Over Chemotherapy Plus Stem Cell Transplant in Second-Line Relapsed or Refractory Large B-cell Lymphoma
June 28, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Treatment With Hepcludex® (Bulevirtide) Was Shown to Achieve Significant Response in Chronic Hepatitis Delta Virus After 24 Weeks
June 24, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Kite Joint Venture - Fosun Kite - Gains the First CAR T-cell Therapy Approval in China
June 23, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead’s Veklury® (Remdesivir) Associated With a Reduction in Mortality Rate in Hospitalized Patients With COVID-19 Across Three Analyses of Large Retrospective Real-World Data Sets
June 21, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead to Present More Than 70 Abstracts From Diverse Liver Disease Programs At The International Liver Congress™ 2021
June 21, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Kite and Shoreline Biosciences Enter Into Strategic Partnership to Develop Novel Allogeneic Cell Therapies
June 17, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.